Artiva Biotherapeutics, Inc. (ARTV) NASDAQ
10.89
-1.63(-13.02%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Artiva Biotherapeutics, Inc.
Address
5505 Morehouse Drive
San Diego, CA 92121
United States of America (the)
Phone
858 267 4467
Website
Sector
Healthcare
Industry
Biotechnology
Employees
96
First IPO Date
July 19, 2024
Key Executives
| Name | Title | Pay | Year Born |
| Fred Aslan | President, Chief Executive Officer & Director | 1.22M | 1976 |
| Peter Flynn | Co-Founder & Strategic Advisor | 499,368 | 1974 |
| Christopher Horan | Chief Technical Operations Officer | 612,234 | 1967 |
| Jennifer Kinsbruner Bush | Chief Operating Officer | 839,214 | 1975 |
| Nicholas Veomett | Vice President of Corporate Development | 0 | N/A |
| Andrew Cronauer | VP, General Counsel & Corporate Secretary | 0 | N/A |
| Benjamin Dewees | Senior Vice President of Regulatory Affairs | 0 | N/A |
| Feng Xu | Senior Vice President of Biometrics | 0 | N/A |
| Thad Huston | CFO and Principal Financial & Accounting Officer | 0 | 1971 |
| Heather Raymon | Senior Vice President of Research & Early Development | 0 | 1965 |
| Subhashis Banerjee | Chief Medical Officer | 0 | 1957 |
| David Moriarty | Senior Vice President of Clinical Operations | 0 | N/A |
Description
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.
